Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
StageZero Life Sciences Ltd
61N1StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada. Address: 70 East Beaver Creek Road, Richmond Hill, ON, Canada, L4B 3B2
Analytics
Precio Objetivo de WallStreet
1.74 CADRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave 61N1
Análisis de dividendos 61N1
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout 61N1
Valoración de la acción 61N1
Finanzas 61N1
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |